Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2021-03-15 (5 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PARIS (75016), Paris
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE 2 M KRIEF : revenue, balance sheet and financial ratios
SELARL PHARMACIE 2 M KRIEF is a French company
founded 5 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PARIS (75016),
this company of category PME
shows in 2024 a net income positive of 141 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE 2 M KRIEF (SIREN 895345023)
Indicator
2024
2023
2022
2021
Revenue
N/C
N/C
N/C
N/C
Net income
140 874 €
143 968 €
241 805 €
91 999 €
EBITDA
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, SELARL PHARMACIE 2 M KRIEF generates positive net income of 141 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2021-2024: 92 k€ -> 141 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
140 874 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 114%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 41%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
113.634%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
40.742%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL PHARMACIE 2 M KRIEF
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2021
2022
2023
2024
Debt ratio
1051.837
240.411
150.576
113.634
Financial autonomy
7.348
24.683
34.413
40.742
Repayment capacity
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
Sector positioning
Debt ratio
113.632024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average-11 pts over 3 years
In 2024, the debt ratio of SELARL PHARMACIE 2 M KRIEF (113.63) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
40.74%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average+14 pts over 3 years
In 2024, the financial autonomy of SELARL PHARMACIE 2 M KRIEF (40.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 262.76. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
262.756
Liquidity indicators evolution SELARL PHARMACIE 2 M KRIEF
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2021
2022
2023
2024
Liquidity ratio
190.765
188.878
232.238
262.756
Interest coverage
None
None
None
None
Sector positioning
Liquidity ratio
262.762024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Excellent+30 pts over 3 years
In 2024, the liquidity ratio of SELARL PHARMACIE 2 M KRIEF (262.76) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Positioning of SELARL PHARMACIE 2 M KRIEF in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELARL PHARMACIE 2 M KRIEF is estimated at
1 966 705 €
(range 1 369 582€ - 2 942 303€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1369k€1966k€2942k€
1 966 705 €Range: 1 369 582€ - 2 942 303€
NAF 5 année 2024
Valuation method used
Net Income Multiple
140 874 €
×
14.0x
=1 966 705 €
Range: 1 369 582€ - 2 942 303€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE 2 M KRIEF with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE 2 M KRIEF
What is the revenue of SELARL PHARMACIE 2 M KRIEF ?
The revenue of SELARL PHARMACIE 2 M KRIEF is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL PHARMACIE 2 M KRIEF profitable?
Yes, SELARL PHARMACIE 2 M KRIEF generated a net profit of 141 k€ in 2024.
Where is the headquarters of SELARL PHARMACIE 2 M KRIEF ?
The headquarters of SELARL PHARMACIE 2 M KRIEF is located in PARIS (75016), in the department Paris.
Where to find the tax return of SELARL PHARMACIE 2 M KRIEF ?
The tax return of SELARL PHARMACIE 2 M KRIEF is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE 2 M KRIEF operate?
SELARL PHARMACIE 2 M KRIEF operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart